FDA Generic Drug Review Boosts US Drug Manufacturing

Original Article by Siddhi Mahatole | Reuters | 5 October 2025

The US Food and Drug Administration (FDA) has announced the launch of a new pilot programme. This programme aims to accelerate the review process for generic drugs. Companies research, develop, and manufacture these drugs entirely within the United States. The initiative aims to incentivise pharmaceutical companies to onshore their operations. It strengthens the domestic supply […]

The US Food and Drug Administration (FDA) has announced the launch of a new pilot programme. This programme aims to accelerate the review process for generic drugs. Companies research, develop, and manufacture these drugs entirely within the United States. The initiative aims to incentivise pharmaceutical companies to onshore their operations. It strengthens the domestic supply…

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here